Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07475572 | A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | PHASE1 | NOT YET_RECRUITING | 120 | — | — | Jun 19, 2026 | Apr 14, 2028 | Mar 16, 2026 | - | — |
AUC0-3w (Cycle 1)
| Arm | Type | Description |
|---|---|---|
| AVT32-DRL_PB | EXPERIMENTAL | AVT32-DRL\_PB will be administered during double blind period and open label period |
| Keytruda | ACTIVE_COMPARATOR | Keytruda will be administered during double blind period |
| Name | Type | Description |
|---|---|---|
| AVT32-DRL_PB | BIOLOGICAL | AVT32-DRL\_PB at a dose 200 mg administered intravenously every 3 weeks. |
| Keytruda | BIOLOGICAL | Keytruda at a dose 200 mg administered intravenously every 3 weeks. |
Inclusion Criteria: * Participants (male/female) ≥18 years of age at the time of signing the ICF. * Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at the time of enrollment. * Participants with Stage IIB, IIC, or III histologically confirmed cutaneous melanoma ...